Hybrid organometallic galectin inhibitors

0558566 - ÚCHP 2023 CZ eng K - Konferenční příspěvek (tuzemská konf.)
Hamala, Vojtěch
Hybrid organometallic galectin inhibitors.
Proceedings of Abstracts. Prague: Institute of Chemical Process Fundamentals of the CAS, 2022 - (Bendová, M.; Wagner, Z.), s. 47-48. ISBN 978-80-86186-24-5.
[Bažant Postgraduate Conference 2022. Prague (CZ), 13.06.2022-14.06.2022]
Institucionální podpora: RVO:67985858
Klíčová slova: organometallic compounds * galectin inhibitors * glycomymetics
Obor OECD: Organic chemistry

Galectins are lectin-type proteins defined by their sequence homology and the ability to bind β-galactosides. Human galectin-1 (Gal-1) and galectin-3 (Gal-3) are involved in tumor progression. Elevated Gal-1 levels are reported for many tumor tissues and Gal-1 contributes to tumor progression including cell migration and tumor immune escape.
Gal-3 is characteristically overexpressed in many cancers and an elevated Gal-3 level is associated with increased invasiveness, metastatic spreading, immunosuppression and angiogenesis. Galectins are also implicated in progression of serious diseases other than cancer e.g., cardiovascular ones, diabetes mellitus, fibrosis, and others. These
properties make galectins promising therapeutic targets.

Trvalý link: http://hdl.handle.net/11104/0332205